These findings were confirmed in thePhase III ADJUVANT/CTONG1104 trial [99],which compared adjuvant platinum doublet chemotherapy to gefitinib incompletely-resected, EGFR-mutated Stage IB-IIIA NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.